Recursion Pharmaceuticals (RXRX) Stock Dropped, So What Is Behind The Move?

How the latest earnings report frames Recursion Pharmaceuticals stock

Recursion Pharmaceuticals (RXRX) has drawn fresh attention after reporting second quarter and first half 2026 results, showing sharply lower sales and revenue alongside a narrower net loss compared with the prior year period.

See our latest analysis for Recursion Pharmaceuticals.

The earnings update appears to have weighed on sentiment in the short term, with Recursion Pharmaceuticals recording a 1-day share price return of 4.53% lower and a 7-day share price return of 1.86% lower. The 90-day share price return of 7.85% higher contrasts with a year-to-date share price return of 24.76% lower and a 1-year total shareholder return of 45.23% lower, which suggests some recent positive momentum following a weaker longer term outcome.

If this earnings move has you reconsidering your exposure to healthcare AI, it could be a good moment to scan a wider peer group using our screener of 44 healthcare AI stocks

Recursion Pharmaceuticals now trades well below both analyst targets and some intrinsic value estimates after the latest results pressured the stock. Is that discount a margin of safety, or a sign the market’s caution is warranted?

Most Popular Narrative: 60% Overvalued

Compared with the last close at $3.16, the most followed narrative on Recursion Pharmaceuticals sets a fair value of $1.97, which points to a meaningful gap between market price and that narrative view.

Recursion Pharmaceuticals (RXRX) one day will be the Palantir of biotechnology! With the CMO transitioning out as well as the former CEO RXRX now has a chance to take off! Vikki Goodman and Najat Khan can now lead RXRX back to respectability and acceptance as a real leader in biotechnology! Once the announcements start coming in on REC-4881 going to Phase 3 and beyond this stock will skyrocket! RXRX finally has the right people in place to do their jobs correctly! Many institutions will soon be coming in with more good news to follow!!!

Read the complete narrative.

This narrative leans heavily on ambitious revenue expansion, improved margins and a future earnings multiple that assumes Recursion Pharmaceuticals can justify a much richer profile than its current loss-making status suggests.

Result: Fair Value of $1.97 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Recursion Pharmaceuticals still faces clear risks if clinical trials stall or partnerships disappoint, which could quickly cool enthusiasm around the current positive narrative.

Find out about the key risks to this Recursion Pharmaceuticals narrative.

Another view on Recursion Pharmaceuticals valuation

The user generated narrative pegs Recursion Pharmaceuticals at a fair value of $1.97 and calls the stock overvalued at $3.16. Our DCF model presents a different picture and suggests RXRX is trading below an estimated future cash flow value of $9.80, which raises the question of which story you trust more.

For readers who want to see how that cash flow based view is built step by step, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Recursion Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mix of enthusiasm and caution around Recursion Pharmaceuticals is clear. Act quickly and review the underlying data, risks, and potential rewards for yourself using the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Recursion Pharmaceuticals?

If you are reassessing Recursion Pharmaceuticals after these results, do not stop there. Broaden your watchlist now so you are not relying on a single story.

• Spot potential mispricing by scanning 50 high quality undervalued stocks that combine solid fundamentals with prices that differ from their assessed worth.
• Prioritize resilience by reviewing 83 resilient stocks with low risk scores that score well on stability and downside protection.
• Get ahead of the crowd by checking the screener containing 18 high quality undiscovered gems before attention and capital move elsewhere.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com